Augurex is developing novel biomarker diagnostic tests. Their primary focus is on the 14-3-3η protein involved in the joint damage process of rheumatoid arthritis (RA). The 14-3-3η protein assay is Health Canada approved as an IVD offered by Dynacare and provided as a laboratory-developed test in the United States through Labcorp and other CLIA certified laboratories.